Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LEXX 
Lexaria Bioscience Corp (LEXX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: LEXX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.33
1 Year Target Price $5.33
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -44.23% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 23.56M USD | Price to earnings Ratio - | 1Y Target Price 5.33 |
Price to earnings Ratio - | 1Y Target Price 5.33 | ||
Volume (30-day avg) 2 | Beta 0.63 | 52 Weeks Range 0.77 - 2.85 | Updated Date 12/2/2025 |
52 Weeks Range 0.77 - 2.85 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.68 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1422.28% |
Management Effectiveness
Return on Assets (TTM) -111.49% | Return on Equity (TTM) -232.15% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 19717457 | Price to Sales(TTM) 33.37 |
Enterprise Value 19717457 | Price to Sales(TTM) 33.37 | ||
Enterprise Value to Revenue 32.01 | Enterprise Value to EBITDA -7.22 | Shares Outstanding 22225846 | Shares Floating 20784944 |
Shares Outstanding 22225846 | Shares Floating 20784944 | ||
Percent Insiders 6.42 | Percent Institutions 7.73 |
Upturn AI SWOT
Lexaria Bioscience Corp
Company Overview
History and Background
Lexaria Bioscience Corp. was founded in 2014. It focuses on improving drug delivery through its DehydraTECHu2122 technology.
Core Business Areas
- DehydraTECHu2122 Technology Licensing: Licenses its DehydraTECHu2122 technology to other companies for use in their products, generating revenue through royalties and licensing fees.
- In-House Research and Development: Conducts research and development to explore new applications of DehydraTECHu2122 technology, particularly in areas like hypertension and nicotine replacement.
Leadership and Structure
Chris Bunka is the CEO. The company has a board of directors and a management team overseeing research, development, and licensing activities.
Top Products and Market Share
Key Offerings
- DehydraTECHu2122 Technology: A patented drug delivery platform that improves the bioavailability and onset time of active pharmaceutical ingredients (APIs) and nutraceuticals. Market share data is not publicly available due to the nature of licensing agreements. Competitors include other drug delivery technology companies such as Nanoform and Liquidia.
Market Dynamics
Industry Overview
The pharmaceutical and nutraceutical industries are increasingly focused on improving drug delivery methods to enhance efficacy and patient outcomes.
Positioning
Lexaria is positioned as a technology provider offering a proprietary drug delivery platform with demonstrated improvements in bioavailability. Its competitive advantage lies in its patented technology and validated efficacy.
Total Addressable Market (TAM)
The TAM for advanced drug delivery systems is estimated to be in the tens of billions of dollars. Lexaria's position is to capture a portion of this market through licensing agreements and potential in-house drug development.
Upturn SWOT Analysis
Strengths
- Patented DehydraTECHu2122 technology
- Improved bioavailability and onset time
- Potential for various applications
- Relatively low operational cost
Weaknesses
- Limited financial resources
- Reliance on licensing revenue
- Limited clinical data for certain applications
- Small Market cap
Opportunities
- Expanding licensing agreements
- Developing proprietary drug formulations
- Partnering with pharmaceutical companies
- Targeting unmet medical needs like hypertension
Threats
- Competition from established drug delivery technologies
- Regulatory hurdles
- Patent infringement
- Inability to secure funding
Competitors and Market Share
Key Competitors
- NANO
- LQDA
Competitive Landscape
Lexaria advantages are its proven technology and the weakness is its limited financial resources compared to larger pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Historical Growth information is not available in this model. Refer to Lexaria's SEC filings (e.g., 10-K, 10-Q) for specific figures.
Future Projections: Future Projections information is not available in this model. Refer to Lexaria's SEC filings (e.g., 10-K, 10-Q) for specific figures.
Recent Initiatives: Recent strategic initiatives include advancing clinical trials for DehydraTECH-CBD in hypertension and exploring applications in nicotine replacement.
Summary
Lexaria Bioscience Corp. is a biotechnology company focused on drug delivery innovation. Its DehydraTECH technology shows promise. However, the company faces financial constraints and must successfully execute its licensing and development strategies. Securing partnerships will be key to long-term growth and success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Lexaria Bioscience Corp. website
- SEC filings
- Industry reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share estimates are based on limited available data and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lexaria Bioscience Corp
Exchange NASDAQ | Headquaters Kelowna, BC, Canada | ||
IPO Launch date 2006-10-10 | CEO & Director Mr. Richard C. Christopher | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://lexariabioscience.com |
Full time employees 7 | Website https://lexariabioscience.com | ||
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. The company's DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, epilepsy, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, and oral products; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.